The sustainability of spending on CAR-T cells in the future depends on the effectiveness of pricing mechanisms in France, discounts and performance-based contracts based on real-life data. Production costs will fall, but the emergence of private, non-profit players would have a major impact on prices. The expected patent losses for drugs with a strong budgetary impact will generate major savings for the French public payer.
PUYOU DE POUVOURVILLE, G. (2024). Les cellules CAR-T : prix, efficience et soutenabilité en France. Bulletin de l’Académie Nationale de Médecine, In press.